Immunotherapy after chemo shows promise for elderly brain cancer patients
NCT ID NCT04022980
First seen Jan 10, 2026 · Last updated May 21, 2026 · Updated 25 times
Summary
This early-phase study tested whether the immunotherapy drug nivolumab could safely improve outcomes for people aged 65 and older with primary central nervous system lymphoma (a rare brain cancer). After completing initial high-dose chemotherapy, 14 participants received nivolumab to help their immune system fight any remaining cancer cells. The goal was to find a safe dose and see if it could delay the cancer from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN AND NERVOUS SYSTEM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Brookline, Massachusetts, 02215, United States
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
The University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UNC Hospitals, The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
Conditions
Explore the condition pages connected to this study.